BLX 1002

Drug Profile

BLX 1002

Alternative Names: BLX-1002

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BEXEL Pharmaceuticals
  • Class Amino acids; Anti-inflammatories; Small molecules
  • Mechanism of Action Interleukin 6 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus; Unspecified

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in USA
  • 24 Nov 2010 No development reported - Phase-II for Type-2 diabetes mellitus in Europe (PO)
  • 11 Sep 2008 Pharmacodynamics data from a preclinical trial Diabetes mellitus presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top